"Lancaster Cancer Center Ltd. provides uncompromising and compassionate care to those affected with cancer for the Lancaster, PA area."

During the past decade, Lancaster Cancer Center conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 2 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Lancaster Cancer Center" #1 sponsor was "Accelerated Community Oncology Research Network" with 4 trials, followed by "Celgene" with 3 trials sponsored, "Novartis Pharmaceuticals" with 2 trials sponsored, "Agennix" with 1 trials sponsored and "CTI BioPharma" with 1 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Lancaster Cancer Center" #1 collaborator was "Bayer" with 2 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Hoffmann-La Roche" with 1 trials as a collaborator, "Janssen, LP" with 1 trials as a collaborator and "Johnson & Johnson Pharmaceutical Research & Development, L.L.C." with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Lancaster Cancer Center" are "Breast Cancer" (3 trials), "Advanced Breast Cancer" (2 trials), "Metastatic Breast Cancer" (2 trials), "Multiple Myeloma" (2 trials) and "Myelodysplastic Syndromes" (2 trials). Many other conditions were trialed in "Lancaster Cancer Center" in a lesser frequency.

Most popular intervention types in "Lancaster Cancer Center" are "Drug" (15 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "gemcitabine hydrochloride" (2 trials), "Avelumab" (1 trials), "Avelumab Weekly" (1 trials), "Bortezomib + Rituximab" (1 trials) and "Capecitabine" (1 trials). Other intervention names were less common.

The vast majority of trials in "Lancaster Cancer Center" are 15 trials for "All" genders, 3 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Lancaster Cancer Center". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 11 completed trials in Lancaster Cancer Center, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Lancaster Cancer Center, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".